Study to Define the Electrocardiogram Effects of a Single Dose of LX4211 in Healthy Subjects

Inclusion Criteria:

- Adult subjects ≥18 to ≤55 years of age

- Vital signs at Screening in the following ranges: systolic blood pressure, 90-140
mmHg; diastolic blood pressure, 50-90 mmHg; heart rate, 45-100 bpm

- Body mass index (BMI) ≥18 and ≤35 kg/sq m

- Able and willing to provide written informed consent

- Nonsmoker and has not used any tobacco products for at least 3 months prior to
Screening

- Willing to adhere to the prohibitions and restrictions specified in this protocol

- Able to tolerate prolonged periods of quiet, motionless, supervised rest

Exclusion Criteria:

- Use of any medication (prescription, over-the-counter, herbal tea, or supplements)
within 5 days of dosing

- Use of any investigational agent or study treatment within 30 days prior to Screening

- Use of any protein or antibody-based therapeutic agents within 3 months prior to
Screening

- Prior exposure to LX4211

- Daily use of cigarettes or any tobacco products within 3 months prior to Screening
and while participating in the study

- History of any major surgery within 6 months prior to Screening

- History of any serious adverse reaction or hypersensitivity to any inactive component
of LX4211

- History of renal disease or significantly abnormal kidney function tests

- History of hepatic disease or significantly abnormal liver function tests

- Women who are breastfeeding or are planning to become pregnant during the study

- History of any active infection within 14 days prior to Screening

- History of alcohol or substance abuse within 2 years prior to Screening

- History of hepatitis B surface antigen (HBsAg), hepatitis C antibody (HCV Ab), HIV-1
or HIV-2

- Presence of clinically significant physical, laboratory, or ECG findings (eg, QTcF
>450 msec for females and QTcF >430 msec for males) at Screening

- >30 premature ventricular beats per hour on the telemetry ECG monitoring at Day -2 of
Period 1

- History of additional risk factors for the presence of a family history of Short QT
Syndrome, Long QT Syndrome, sudden unexplained death at a young age (<=40 years),
drowning or sudden infant death syndrome in a first degree relative (ie, biological
parent, sibling, or child)

- Any skin condition likely to interfere with ECG electrode placement or adhesion

- Any skin condition likely to interfere with ECG electrode placement or adhesion

- Donation or loss of >400 mL of blood or blood product within 3 months prior to
Screening

- Positive urine glucose during Screening

- Positive pregnancy test during Screening

- Positive urine screen for drugs of abuse during Screening

- Positive urine test for alcohol during Screening

- Inability or difficulty swallowing whole tablets or capsules

- Unable or unwilling to communicate or cooperate with the Investigator for any reason